IL17A and metabolic dysfunction-associated steatohepatitis: IL-17 deficiency (Il17a-/-) in the MCD-induced models was shown to reduce liver fibrosis (147), while treating the HFD-induced MASH model with recombinant IL-17 worsened fibrosis development (133).